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Background: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity 
and mortality worldwide. Despite a high prevalence of smoking and respiratory symptoms, 
two recent population-based studies in Russia found a relatively low prevalence of obstruc-
tive lung function. Here, we investigated the prevalence of both obstructive lung disease and 
respiratory symptoms in a population-based study conducted in two Russian cities and 
compared the findings with a similar study from Norway conducted in the same time period.
Methods: The study population was a sub-sample of participants aged 40–69 years participating 
in the Know Your Heart (KYH) study in Russia in 2015–18 (n=1883) and in the 7th survey of the 
Tromsø Study (n=5271) carried out in Norway in 2015–16 (Tromsø 7) who participated in 
spirometry examinations. The main outcome was obstructive lung function (FEV1/FVC ratio< 
lower limit of normal on pre-bronchodilator spirometry examination) with and without respiratory 
symptoms (chronic cough and breathlessness). In those with obstructive lung function, awareness 
(known diagnosis) and management (use of medications, smoking cessation) were compared.
Results: The age-standardized prevalence of obstructive lung function was similar among 
men in both studies (KYH 11.0% vs Tromsø 7 9.8%, p=0.21) and higher in the Norwegian 
(9.4%) than Russian (6.8%) women (p=0.006). In contrast, the prevalence of obstructive lung 
function plus respiratory symptoms was higher in Russian men (KYH 8.3% vs Tromsø 7 
4.7%, p<0.001) but similar in women (KYH 5.9% vs Tromsø 7 6.4%, p=0.18). There was a 
much higher prevalence of respiratory symptoms in Russian than Norwegian participants of 
both sexes regardless of presence of obstructive lung function.
Conclusion: The prevalence of respiratory symptoms was strikingly high among Russian 
participants but this was not explained by a higher burden of obstructive lung function on 
spirometry testing in comparison with Norwegian participants. Further work is needed to 
understand the reasons and health implications of this high prevalence of cough and 
breathlessness.
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Introduction
Despite recent declines, premature mortality remains a major public health concern 
in Russia.1 Respiratory diseases contribute substantially with Chronic Obstructive 
Pulmonary Disease (COPD) estimated as the 14th leading cause of death in Russia 
in 2016 while respiratory infection was the 6th leading cause of death.1 COPD is 
strongly related to cardiovascular disease (CVD)2,3 and in many patients with 
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COPD cardiovascular disease is the underlying cause of 
death.4–6 In Russia, there is a high prevalence of smoking 
in men,7 which is a major risk factor for COPD. 
Occupational exposure to vapours, dust and fumes may 
also lead to increased risk among certain groups.8 It is 
important to quantify and understand the burden of COPD 
within Russia, particularly in a country with one of the 
highest rates of CVD mortality in the world.9
Four population-based surveys have found high levels 
of reporting of respiratory symptoms in the Russian gen-
eral population10–13 but only two of these studies also 
included spirometry testing.11,13 In a cross-sectional sur-
vey of 7164 adults aged 18 or older living in 12 regions of 
Russia (2010–2011), spirometry was used to diagnose 
COPD among those who reported any respiratory symp-
toms or risk factors for chronic respiratory disease11. 
Chuchalin et al11 extrapolated results from spirometry 
testing in this study to estimate that the prevalence of 
symptomatic COPD (symptoms plus forced expiratory 
volume in 1 second (FEV1): Forced vital capacity (FVC) 
ratio<0.7) in the total study population was 15.3%. 
Estimates of airway obstruction from the earlier HAPIEE 
study (2002–2005) from 6875 men and women aged 
45–69 years old in the city of Novosibirsk were even 
higher at 19.5% (23.5% in men and 16.0% in women) 
using a broader definition of airway obstruction on spiro-
metry (FEV1/FVC ratio <0.7 or FEV1,<80%).14 However, 
a study of 2975 adults aged 35–70 living in North West 
Russia (2012–13) found a substantially lower prevalence 
of airway obstruction of 6.8% using a fixed FEV1:FVC 
ratio<0.7 and 4.8% using the Global Lung Initiative Lower 
Limit of Normal (GLI-LLN) cut off with a substantial sex 
difference (higher in men (9.6%) than women (4.8%)).13 
This was consistent with estimates from pre-bronchodila-
tor spirometry from a later study of 5899 adults aged 
40–94 in the Russian region of Bashkortostan which 
found a prevalence of airway obstruction using LLN of 
5.8% (6.8% using fixed cut point).15 These prevalence 
estimates are lower than might be expected given the 
high burden of smoking7 and self-reported respiratory 
symptoms10–13 in the Russian general population.
In quantifying the prevalence and relative disease burden 
from COPD in Russia findings need to be compared in context 
with studies from other populations. However, making com-
parisons between population-based studies is complex. 
Estimated prevalence of COPD can vary widely depending 
on the criteria used for case definition.16,17 Prevalence of 
COPD in Norway, a neighbouring country to Russia with a 
different mortality and risk factor profile, shows considerable 
variation. Estimates from the BOLD study site in Bergen 
(2006) which used spirometry only found the prevalence was 
11% using postbronchodilator fixed cut point among adults 
aged 52–60.18 Findings from the population-based HUNT-3 
study in the county of Nord-Trøndelag (2006–2008) found a 
prevalence of 14.5% using a fixed cut point and 7.3% from 
LLN in adults aged over 40 on pre-bronchodilator spirometric 
assessment.19 Analyses of changes in COPD prevalence over 
time within the Tromsø Study in the municipality of Tromsø 
have shown COPD prevalences have been declining since 
2001 in line with declines in smoking, with the most recent 
estimates from 2015–2016 of 9.7% in men and 10.0% in 
women aged 40–84 using LLN and 5.6% in both sexes when 
including respiratory symptoms within the definition.20 
However, to compare estimated COPD prevalence from 
Russia with studies from other settings is difficult given differ-
ences in age range, COPD definition and time frames.
Here we investigated prevalence of both obstructive 
lung disease and respiratory symptoms in a population- 
based study conducted in two Russian cities and compared 
the findings with a similar study from Norway conducted 
in the same time period using the same definitions of 
COPD for both studies. Among those with evidence of 
COPD, we compared levels of awareness and management 
(smoking cessation, use of pharmacological treatments) 
between the study populations.
Methods
Study Populations
The study population was a sub-sample of participants 
aged 40–69 years taking part in the two population-based 
health surveys the Know Your Heart (KYH) Study21 con-
ducted in the Russian cities of Arkhangelsk and 
Novosibirsk (2015–18) and the seventh survey of the 
Tromsø Study22 (Tromsø 7) conducted in the Norwegian 
municipality of Tromsø (2015–16). These studies were 
conducted in parallel and several aspects of data collection 
between the studies have been harmonized (including the 
measurement of breathlessness, quality criteria for spiro-
metry and ATC coding of medications) providing a unique 
opportunity to compare lung function between general 
population samples in both countries.
Know Your Heart Study Sample (Russia)
Participants were identified from a population register of 
addresses and a random sample stratified by age, sex and 
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district was selected (n=15,284 aged 40–69). Trained inter-
viewers visited the addresses and invited participants to 
take part in the study. Participants who agreed to take part 
completed an interviewer-administered questionnaire 
which included questions on socio-demographic factors 
and self-reported morbidities (n=4654 aged 40–69). 
Participants were then invited to a health check which 
included a further questionnaire and a comprehensive 
medical examination (n= 4044 aged 40–69). Spirometry 
was an additional component of the health check offered to 
approximately 50% of participants. Selection of partici-
pants, for practical reasons, was determined by the day of 
the week that medical professionals trained in these pro-
cedures were available. The days of the week when spiro-
metry was offered were varied throughout the fieldwork in 
order to minimize selection bias. Contra-indications for 
spirometry were: chest infection in the last month (ie, 
influenza, bronchitis, severe cold, pneumonia); history of 
detached retina; myocardial infarction in the past month; 
surgery to eyes, chest or abdomen in last 3 months; history 
of a collapsed lung; pregnancy (1st or 3rd trimester); 
currently on medications for tuberculosis.
Uptake was high among those to whom it was offered 
(94.9% of participants invited to spirometry completed the 
examination) and in total lung function data are available 
for 45.7% of participants who attended the health check 
(n=1883 aged 40–69). Data on use of medications, smok-
ing and self-report of respiratory symptoms were collected 
for all participants attending the health check.
The Tromsø Study Sample (Norway)
All inhabitants aged 40 and older were invited to take part 
in Tromsø 7 (n=32,591). Participants underwent a basic 
examination which involved questionnaires and inter-
views, biological sampling and clinical examinations 
(n=21,083 of which n=17,646 were aged 40–69). A subset 
of participants (randomly pre-marked before attendance 
with addition of previous participants from Tromsø 6 
2007–2008) were invited to take part in extended exam-
inations including spirometry. There were no contra-indi-
cations for spirometry assessment. In total spirometry was 
conducted on 5217 participants in the required age range.
Spirometry Assessment
In KYH Spirometry was conducted using 6800 
Pneumotrac spirometers (Vitalograph®, UK) and in 
Tromsø 7 using Vmax® Encore devices (Sensormedics® 
Corporation, USA). The spirometry examination took 
place alongside several other clinical examinations in 
both studies. Post-bronchodilator measurements were not 
taken in order to minimize burden for participants.
For both studies, three measurements were taken. If 
less than 2 of the measures were acceptable then additional 
measurements were taken up to a maximum of eight. 
Maximum FEV1 and maximum FVC were used in ana-
lyses not necessarily from the same blow. Following data 
collection acceptability and reproducibility of results were 
determined by 1) removing blows where FEV1 was less 
than 300 mL and 2) excluding values where FEV3 was the 
same or greater than FVC. For Tromsø 7 the curves from 
the study were assessed and cleaned manually by the study 
team responsible for data collection. For KYH cases where 
the difference between maximum values and the second 
highest value for FEV1 and FVC were greater than 250 
mL were evaluated. In cases where the maximum value is 
found to be an outlier (difference between 2nd and 3rd 
max<250mL) compared to other values the next highest 
value was used. Otherwise, the maximum was used.
Outcome
The primary outcome definition was pre-bronchodilator 
FEV1: FVC ratio<Lower Limit Normal (LLN) with and 
without self-reported respiratory symptoms. LLN was cal-
culated from the GLI LLN equations23 specifying ethnicity 
as white using GLI-2012 Desktop Software for Large Data 
Sets.24 The secondary definition of FEV1: FVC ratio<0.7 
with and without symptoms was used to investigate impact 
of definition of the findings.
Respiratory symptoms were defined as chronic cough 
and/or breathlessness. Breathlessness was measured in 
both studies using the MRC breathlessness scale.25 
Breathlessness was categorised as grade 2 breathlessness 
or above (equivalent to grade 1 on the modified mMRC 
dyspnoea scale) “short of breath when hurrying on the 
level or walking up a slight hill”. Chronic cough was 
defined from the questions in Table 1. If participants 
answered “yes” to any of the questions on cough they 
were considered to have a chronic cough. Sensitivity ana-
lyses were conducted using a stricter definition of both 
breathlessness and cough to define respiratory symptoms.
Risk Factors
Risk factors measured were age, sex, education, smoking 
status (never, ex-smoker, current smoker) and pack-year 
history calculated from questions on years smoked and num-
ber of cigarettes smoked per day, and body mass index (BMI) 
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calculated from measured height and weight. Education was 
coded into three categories (lower, middle and higher) based 
on the education system within each country. In KYH these 
groups were lower (incomplete secondary and vocational no 
secondary), middle (complete secondary, vocational and sec-
ondary, specialised secondary) and higher (incomplete 
higher, higher) education. For Tromsø 7, these were lower 
(primary) middle (upper secondary) and higher (university/ 
university college) education. Current smokers in both stu-
dies included participants those who smoked less than daily 
(KYH n=26; Tromsø 7 n=350).
An indicator of existing CVD based on self-reported 
stroke and/or myocardial infarction was also included as an 
important factor associated with respiratory disease with 
different expected prevalence between the two studies.
Awareness of COPD
Awareness was assessed from self-report of chronic lung 
disease. In KYH this was assessed with the question 
“Have you ever been told by a doctor (been diagnosed) 
that you have chronic bronchitis/COPD?” In Tromsø 7 this 
question was “Have you ever had, or do you have chronic 
bronchitis/emphysema/COPD?”. Participants who reported 
they had a diagnosis either now or previously were cate-
gorised as aware of COPD status.
Management of COPD
Management of COPD was compared on two levels: smoking 
cessation and pharmacological management according to 
Global Initiative for Chronic Obstructive Disease (GOLD) 
guidelines.26
Levels of smoking cessation were assessed by comparing 
the proportion of those with obstructive lung function ± 
respiratory symptoms who were current smokers. In the 
KYH two additional questions on smoking cessation advice 
and assistance were asked to participants who reported they 
were smokers “Have you ever been advised by a medical 
professional (your GP, cardiologist, any other physician) to 
stop smoking?” and “was any assistance offered?”
For both studies, data on use of current medications 
were collected and coded in accordance with the 
International WHO Anatomical Therapeutic Chemical 
(ATC) classification system version 2016.27 
Pharmacological treatment was compared across two 
domains of use applicable to participants in population- 
based studies: maintenance treatment and short-acting 
symptomatic treatment. Maintenance treatment was 
defined as the use of long-acting muscarinic antagonists 
(R03BB) (LAMA); long-acting beta-2 agonists 
(R03AC12, 13, 18 and 19) (LABA); combination of 
long-acting beta-2 agonists with steroids or long-acting 
muscarinics (R03AK, R03AL); theophylline (R03DA04); 
roflumilast (R03DX07)). Short-acting symptomatic treat-
ment was defined as the use of short-acting beta agonists 
(R03AC02, 03, 04)).
Statistical Analysis
The prevalence of obstructive lung function (plus symptoms) 
was compared by study and sex with 1) standardisation for 
Table 1 Questions on Chronic Cough
Know Your Heart Tromsø 7
Do you usually cough first thing in the morning in 
winter?
Do you cough about daily for some periods of the year?
Do you usually cough during the day or at night in 
winter?
If you cough about daily for some periods of the year, is your cough productive?
Do you cough like this on most days for as much as 
three months each year?
If you cough about daily for some periods of the year, have you had this kind of cough 
for as long as 3 months in each of the last two years?
Do you usually bring up phlegm from your chest first 
thing in the morning in winter?
Do you usually bring up any phlegm from your chest 
during the day- or at night – in winter?
Do you bring up phlegm like this on most days for as 
much as three months each year?
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age to the 2013 Standard European population and 2) strati-
fication across 10 year age bands.
Differences in the studies in the associations with age, 
sex, education, smoking, BMI and self-reported CVD were 
investigated by fitting separate logistic regression models 
with the outcomes 1) obstructive lung function and 2) 
obstructive lung function plus symptoms and testing for 
interactions between study and each risk factors using 
likelihood ratio tests.
Interaction between age and pack-year history was 
investigated within each study by fitting logistic regression 
models with 1) obstructive lung function and 2) obstruc-
tive lung function plus symptoms as the outcomes adjusted 
for sex (and city for KYH) with and without interaction 
terms between age and pack-year history and comparing 
these using likelihood ratio tests. These interactions were 
investigated because of observed differences in the distri-
bution of age and pack-year history between the studies.
Prevalence of current smoking, self-report of diagnosis, 
and medication use in those with obstructive lung disease 
was compared between the studies across levels of 
reported respiratory symptoms (none, one symptom or 
both symptoms). Differences between studies were inves-
tigated using separate logistic regression models for each 
outcome and study as the exposure adjusted for 1) age and 
sex and 2) age, sex and respiratory symptoms.
Interaction by sex and study was investigated using 
likelihood ratio tests and if there was evidence suggesting 
interaction results were presented stratified by sex.
Sensitivity Analysis to Investigate the 
Impact of Missing Data
The main analyses were restricted to complete case 
analysis.
As spirometry was conducted in a sub-set of participants 
in both studies, the potential impact of this was investigated 
by comparing the characteristics of those with spirometry 
data to the full sample (all health check attendees for KYH, 
all basic examination attendees Tromsø 7).
To investigate whether differences in those included and 
excluded could have affected the estimates of prevalence of 
obstructive lung function (<LLN) sensitivity analyses were 
conducted. Separate multiple imputation models were fitted 
for each study imputing the outcome in those who did not 
complete the spirometry examination from age, sex, educa-
tion, BMI, self-reported CVD, smoking status, pack-year 
history, chronic cough and MRC breathlessness scale.
Results
In total there were 1883 participants in KYH (41.8% men) 
and 5217 participants in Tromsø 7 (45.7% men) aged 40–69 
with data from spirometry. Characteristics of participants by 
sex and study are shown in Table 2. Although the proportion 
of men in the oldest age group was higher for the Tromsø 7 
men, the KYH men had a higher smoking pack-year history.
There was no evidence for a difference in sex-stratified 
prevalences of obstructive lung function between the two 
Russian sites after adjusting for age, and due to small 
numbers findings from both sites were pooled.
Prevalence of Obstructive Lung Function 
and Respiratory Symptoms
The crude prevalence of obstructive lung function and 
respiratory symptoms by sex and study is shown in Table 2. 
Findings after age-standardisation were similar to the crude 
findings. Among women the age-standardized prevalence of 
obstructive lung function defined by LLN was higher (age- 
adjusted p value=0.006) in the Tromsø 7 women (9.4%) 
compared to the KYH women (6.8%) while there was no 
evidence for a difference by study in men (KYH men 11.0%; 
Tromsø 7 men 9.8% age-adjusted p value=0.21).
The prevalence of reporting respiratory symptoms 
among those with obstructive lung function was substan-
tially higher in KYH than Tromsø 7 in both men and 
women across all ages (Figure 1A and B). The age-stan-
dardized prevalence of COPD defined as obstructive lung 
function and one or more respiratory symptom was 8.3% 
in KYH men and 4.7% in Tromsø 7 men (age-adjusted p 
value<0.001). In women, this was 5.9% in KYH and 4.6% 
in Tromsø 7 (age-adjusted p value=0.18).
The positive predictive value of any respiratory symp-
toms for identifying obstructive lung function was low in 
both studies (10.4% in KYH; 14.4% in Tromsø 7). The 
marked differences in reporting of respiratory symptoms 
between the studies were also seen in those without obstruc-
tive lung function on spirometry (Supplementary Figure 1).
Interaction in the Between-Study 
Differences by Sex, Age, Education, 
Smoking, BMI and Self-Reported CVD
The associations between obstructive lung function and age, 
sex, education, smoking, BMI and self-reported CVD morbid-
ity and interactions by study are shown in Table 3. There was 
no evidence for interaction in associations with age, education, 
smoking, BMI or self-reported CVD morbidity between the 
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Table 2 Characteristics of Participants by Sex and Study. Know Your Heart Study 2015–2018 and Tromsø Study 2015–2016
Know Your Heart Tromsø 7
Women Men Women Men
N (%) N (%) N (%) N (%)
Total sample 1096 (100) 787 (100) 2831 (100) 2386 (100)
Age, years 40–49 331 (30.2) 238 (30.2) 553 (19.5) 471 (19.7)
50–59 384 (35.0) 259 (32.9) 716 (25.3) 526 (22.1)
60–69 381 (34.8) 290 (36.9) 1562 (55.2) 1389 (58.2)
City Arkhangelsk 538 (49.1) 405 (51.5) – –
Novosibirsk 558 (50.9) 382 (48.5) – –
Education Lower 58 (5.3) 63 (8.0) 660 (23.6) 537 (22.7)
Middle 586 (53.5) 405 (51.5) 782 (28.0) 717 (30.4)
Higher 452 (41.2) 319 (40.5) 1356 (48.5) 1107 (48.9)
Missing 0 0 33 25
Smoking status Never 744 (67.9) 217 (27.6) 958 (34.1) 856 (36.3)
Ex-smoker 173 (15.8) 285 (36.3) 1453 (51.7) 1131 (47.9)
Current smoker 179 (16.3) 283 (36.1) 400 (14.2) 374 (15.8)
Missing 0 2 20 25
Smoking pack years among ever smokers >0<10 184 (60.1) 85 (15.5) 940 (52.6) 564 (38.2)
10–19 54 (17.7) 104 (18.9) 478 (26.8) 433 (29.3)
20–29 45 (14.7) 163 (29.6) 246 (13.8) 220 (14.9)
30–39 14 (4.6) 109 (19.8) 83 (4.6) 167 (11.3)
40+ 9 (2.9) 89 (16.2) 40 (2.2) 92 (6.2)
Missing 46 18 66 29
Body mass index, kg/m2 <18.5 13 (1.2) 9 (1.2) 29 (1.0) 2 (0.1)
18.5–24.9 317 (29.0) 218 (27.7) 1119 (39.6) 572 (24.0)
25–29.9 361 (33.0) 349 (44.4) 1095 (38.7) 1208 (50.7)
30–34.9 259 (23.7) 166 (21.1) 430 (15.2) 471 (19.8)
>35 144 (13.2) 44 (5.6) 154 (5.5) 130 (5.5)
Missing 2 1 4 3
Self-reported Cardiovascular co-morbidity (stroke and/or myocardial 
infarction)
Yes 67 (6.3) 94 (12.3) 80 (3.0) 178 (7.8)
Missing 24 21 127 98
Chronic cough Yes 455 (41.8) 335 (43.2) 397 (14.2) 412 (17.5)
Missing 7 11 27 31
Breathlessness grade 2 Yes 672 (62.2) 306 (39.3) 854 (30.2) 593 (24.9)
Missing 15 8 7 8
(Continued)
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studies but there was strong evidence for a difference in 
association with sex (p=0.002). Women had lower odds of 
obstructive lung disease than men in KYH but similar odds as 
men in Tromsø 7. The between-study difference found in 
women was removed by additional adjustment for smoking 
history (odds ratio for association of study in women adjusted 
for age and pack-year history 1.02 95% CI 0.76, 1.37).
The equivalent associations between obstructive lung 
function plus respiratory symptoms are shown in Table 4. 
In contrast to findings for obstructive lung function, there 
was strong evidence for higher odds of obstructive lung 
function plus symptoms in the KYH participants after adjust-
ment for sex and age. This was seen in all ages and across 
categories of education and self-reported CVD morbidity. 
However, there was some evidence of effect modification 
by sex (p=0.06), pack years history (p=0.01) and smoking 
status (p=0.02) with largest between-study effect in never 
smokers and no evidence for a between-study effect in hea-
vier smokers, and in women.
In sensitivity analysis using the stricter definition of 
respiratory symptoms (Supplementary Table 1), the 
between study difference was larger. There remained 
evidence for effect modification by pack-years smoked 
(no between study difference in heavier smokers >20 
pack-years) but there was no evidence for effect mod-
ification by the other risk factors.
Observed interactions between age and pack-year history 
within each study are shown in Supplementary Table 2. 
There was some evidence for interaction between age and 
pack-year history after adjusting for sex for the outcome 
obstructive lung function for Tromsø 7 with stronger associa-
tion between pack-year history and age in the older partici-
pants (p=0.06). Conversely, there was good evidence for 
interaction between age and smoking pack-year history for 
obstructive lung function plus one of more respiratory symp-
toms but with stronger association between pack-year history 
and the outcome in the younger age groups (p=0.01). There 
was no evidence for interactions between age and pack-year 
history with obstructive lung function for KYH (p=0.18) or 
obstructive lung function plus 1 or more symptoms in 
Tromsø 7 (p=0.46).
Awareness and Management Among 
Those with Obstructive Lung Function
The levels of awareness and management among those 
with obstructive lung function by study, sex and reported 
Table 2 (Continued). 
Know Your Heart Tromsø 7
Women Men Women Men
N (%) N (%) N (%) N (%)
Respiratory symptoms None 283 (26.4) 316 (41.0) 1740 (62.2) 1517 (64.6)
Either cough or 
breathless
467 (43.5) 273 (35.5) 873 (31.2) 666 (28.4)
Both cough and 
breathless
324 (30.2) 181 (23.5) 184 (6.6) 164 (7.0)
Missing 22 17 34 39
FEV1: FVC ratio<0.7 Yes 123 (11.2) 154 (19.6) 542 (19.2) 526 (22.1)
FEV1: FVC ratio<LLN* Yes 75 (6.8) 88 (11.2) 290 (10.2) 234 (9.8)
FEV1: FVC ratio<0.7 plus symptoms** Yes 104 (9.6) 113 (14.6) 257 (9.2) 237 (10.1)
Missing 22 17 34 39
FEV1: FVC ratio<LLN* plus symptoms** Yes 64 (5.9) 67 (8.6) 151 (5.4) 123 (5.2)
Missing 22 17 34 39
Ever diagnosed Yes 216 (19.7) 108 (13.8) 96 (3.5) 78 (3.4)
Missing 1 3 97 61
Notes: *GLI LLN (z-score for FEV1/FVC ratio<-1.64). **Symptoms defined as cough and/or breathlessness.
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respiratory symptoms are shown in Table 5. There was 
evidence for a difference in the between-study association 
with current smoking by sex therefore associations for 
current smoking are shown stratified by sex. There was 
no evidence for an interaction between sex and study for 
levels of awareness (test for interaction p=0.44) and phar-
macological managements (maintenance treatment test for 
interaction p=0.37; relief of symptoms p=0.91).
Awareness of COPD
There was strong evidence that awareness of COPD was 
lower among the Tromsø 7 participants (age and sex 
adjusted odds ratio 0.29 (95% CI 0.19, 0.44). However, 
awareness was strongly related to reporting of respiratory 
symptoms (Table 5) and on adjustment for respiratory 
symptoms this association was substantially reduced 









40-49 40-49 50-59 50-59 60-69 60-69
KYH Tromsø 7 KYH Tromsø 7 KYH Tromsø 7
%
Age group (years) and study
Obstructive lung function + cough AND breathless (KYH)
Obstructive lung function + cough OR breathless (KYH)
Obstructive lung function (no respiratory symptoms) (KYH)
Obstructive lung function + cough AND breathless (Tromsø 7)
Obstructive lung function + cough OR breathless (Tromsø 7)









40-49 40-49 50-59 50-59 60-69 60-69
KYH Tromsø 7 KYH Tromsø 7 KYH Tromsø 7
%
Age group (years) and study
A
B
Obstructive lung function + cough AND breathless (KYH)
Obstructive lung function + cough OR breathless (KYH)
Obstructive lung function (no respiratory symptoms) (KYH)
Obstructive lung function + cough AND breathless (Tromsø 7)
Obstructive lung function + cough OR breathless (Tromsø 7)
Obstructive lung function (no respiratory symptoms (Tromsø 7)
Figure 1 Prevalence of obstructive lung disease (FEV1: FVC Ratio<GLI LLN) with and without respiratory symptoms by age and study in men and women. (A) Prevalence of 
obstructive lung disease (FEV1: FVC Ratio<GLI LLN) with and without respiratory symptoms in men. (B) Prevalence of obstructive lung disease (FEV1: FVC Ratio<GLI LLN) 
with and without respiratory symptoms in women.
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Table 3 Association Between Obstructive Lung Disease and Sex, Age, Education, Body Mass Index and Smoking by Study (Ages 
40–69). Know Your Heart Study 2015–2018 and Tromsø Study 2015–2016
KYH Tromsø 7 Odds Ratio 
for Study 
KYH/Tromsø 






for Age and Sex
Prevalence n/N 
(%)
Odds Ratio Age, 
Sex and City 
Adjusted 
Association with 




Odds Ratio Age and 
Sex Adjusted 
Association with 
Risk Factor (95% CI)
Total 163/1883 (8.7) 524/5217 (10.0) 0.89 (0.74, 1.07) –
Sex Men 88/787 (11.2) 1.00 (ref) 290/2831 (10.2) 1.00 (ref) 1.17 (0.90, 1.52) P=0.002
Women 75/1096 (6.8) 0.59 (0.43, 0.81) 234/2386 (9.8) 1.06 (0.88, 1.27) 0.69 (0.53, 0.90)
Age, years 40–49 43/569 (7.6) 1.00 (ref) 99/1024 (9.7) 1.00 (ref) 0.77 (0.53, 1.12) P=0.67
50–59 53/643 (8.2) 1.10 (0.73, 1.68) 108/1242 (8.7) 0.88 (0.67, 1.27) 0.95 (0.67, 1.34)
60–69 67/671 (10.0) 1.35 (0.91, 2.02) 317/2951 (10.7) 1.13 (0.89, 1.43) 0.92 (0.70, 1.21)
Test for trend P=0.13 P=0.15
Education Lower 19/121 (15.7) 1.65 (0.96, 2.85) 161/1197 (13.5) 1.55 (1.22, 1.99) 1.23 (0.73, 2.07) P=0.13
Middle 93/991 (9.4) 1.00 (ref) 135/1499 (9.0) 1.00 (ref) 1.12 (0.84, 1.48)
Higher 51/771 (6.6) 0.71 (0.49, 1.01) 220/2463 (8.9) 0.99 (0.79, 1.24) 0.73 (0.53, 1.00)
Test for trend P=0.004 P<0.001
Smoking 
status
Never 46/961 (4.8) 1.00 (ref) 93/1814 (5.1) 1.00 (ref) 0.92 (0.64, 1.34) P=0.82
Ex-smoker 38/458 (8.3) 1.73 (1.08, 2.77) 266/2584 (10.3) 2.10 (1.64, 2.68) 0.80 (0.56, 1.15)
Current 
smoker






46/961 (4.8) 1.00 (ref) 93/1814 (5.1) 1.00 (ref) 0.92 (0.64, 1.34) P=0.90
>0<10 21/269 (7.8) 1.80 (1.04, 3.10) 106/1504 (7.1) 1.39 (1.04, 1.86) 1.04 (0.63, 1.73)
10–19 16/158 (10.1) 2.59 (1.37, 4.87) 121/911 (13.3) 2.87 (2.16, 3.82) 0.92 (0.52, 1.65)
20–29 32/208 (15.4) 4.59 (2.66, 7.91) 92/466 (19.7) 4.64 (3.40, 6.34) 0.83 (0.51, 1.37)
30–39 23/123 (18.7) 5.62 (3.02, 10.47) 59/250 (23.6) 6.13 (4.25, 8.84) 0.82 (0.47, 1.43)
40+ 22/98 (22.5) 7.55 (3.98, 14.32) 35/132 (26.5) 7.14 (4.56, 11.17) 0.70 (0.35, 1.41)




<18.5 8/22 (36.4) 4.14 (1.65, 10.39) 11/31 (35.5) 3.67 (1.73, 7.78) 0.79 (0.18, 3.52) P=0.60
18.5–24.9 69/535 (12.9) 1.00 (ref) 222/1691 (13.1) 1.00 (ref) 1.15 (0.85, 1.55)
25–29.9 44/710 (6.2) 0.39 (0.26, 0.59) 203/2303 (8.8) 0.62 (0.51, 0.77) 0.70 (0.50, 0.99)
30–34.5 25/425 (5.9) 0.39 (0.24, 0.63) 60/901 (6.7) 0.46 (0.34, 0.62) 0.92 (0.56, 1.50)
>35 16/188 (8.5) 0.64 (0.36, 1.14) 26/284 (9.2) 0.66 (0.43, 1.02) 0.93 (0.47, 1.82)




No 150/1710 (8.8) 1.00 (ref) 478/4799 (10.0) 1.00 (ref) 0.92 (0.75, 1.12) 0.54
Yes 13/167 (7.8) 0.73 (0.40, 1.33) 28/264 (10.6) 1.04 (0.69, 1.57) 0.72 (0.35, 1.46)
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Table 4 Association Between Obstructive Lung Disease with Respiratory Symptoms (Cough and/or Breathlessness) and Sex, Age, 
Education, Body Mass Index and Smoking by Study (Ages 40–69). Know Your Heart Study 2015–2018 and Tromsø Study 2015–2016
KYH Tromsø 7 Odds Ratio 
for Study 
KYH/Tromsø 
7 Adjusted for 
Age and Sex
Likelihood 







Odds Ratio Age, 
Sex and City 
Adjusted 
Association with 




Odds Ratio Age and 
Sex Adjusted 
Association with Risk 
Factor (95% CI)
Total 129/1844 (7.0) 272/5144 (5.3) 1.46 (1.17, 1.83)
Sex Men 65/770 (8.4) 1.00 (ref) 121/2347 (5.1) 1.00 (ref) 1.78 (1.30, 2.46) P=0.06
Women 64/1074 (6.0) 0.69 (0.48, 0.99) 151/2797 (5.4) 1.06 (0.83, 1.35) 1.23 (0.91, 1.68)
Age, years 40–49 31/559 (5.5) 1.00 (ref) 37/1015 (3.7) 1.00 (ref) 1.58 (0.97, 2.57) P=0.84
50–59 44/629 (7.0) 1.29 (0.80, 2.07) 56/1224 (4.6) 1.26 (0.83, 1.93) 1.58 (1.05, 2.37)
60–69 54/656 (8.2) 1.52 (0.96, 2.40) 179/2905 (6.2) 1.74 (1.21, 2.49) 1.36 (0.99, 1.87)
Test for trend P=0.07 P<0.001
Education Lower 15/117 (12.8) 1.64 (0.90. 3.00) 119/1170 (10.2) 2.17 (1.59, 2.95) 1.34 (0.75, 2.38) P=0.67
Middle 74/968 (7.6) 1.00 (ref) 71/1483 (4.8) 1.00 (ref) 1.79 (1.27, 2.52)
Higher 40/759 (5.3) 0.69 (0.46, 1.03) 76/2437 (3.1) 0.65 (0.47, 0.91) 1.76 (1.18, 2.62)
Test for trend P=0.007 P<0.001
Smoking 
status
Never 37/943 (3.9) 1.50 (0.87, 2.59) 27/1800 (1.5) 1.00 (ref) 2.50 (1.49, 4.21) P=0.02
Ex-smoker 25/451 (5.5) 1.00 (ref) 138/2563 (5.4) 3.55 (2.33, 5.39) 1.19 (0.75, 1.87)
Current 
smoker





37/943 (3.9) 1.00 (ref) 27/1800 (1.5) 1.00 (ref) 2.50 (1.49, 4.21) P=0.01
>0<10 18/264 (6.8) 1.98 (1.10, 3.56) 41/1491 (2.8) 1.80 (1.10, 2.94) 2.89 (1.57, 5.30)
10–19 13/157 (8.3) 2.88 (1.44, 5.78) 65/898 (7.2) 5.09 (3.22, 8.04) 1.46 (0.75, 2.83)
20–29 23/200 (11.5) 4.44 (2.40, 8.21) 64/464 (13.8) 10.31 (6.47, 16.43) 1.01 (0.57, 1.79)
30–39 17/120 (14.2) 5.37 (2.67, 10.81) 41/250 (16.4) 13.36 (7.97, 22.39) 0.95 (0.50, 1.80)
40+ 19/98 (19.4) 8.45 (4.22, 16.90) 28/131 (21.4) 18.40 (10.34, 32.75) 0.66 (0.31, 1.40)




<18.5 5/21 (23.8) 3.00 (1.04, 8.64) 7/31 (22.6) 4.78 (2.00, 11.46) 0.94 (0.16, 5.45) P=0.14
18.5–24.9 53/525 (10.1) 1.00 (ref) 95/1672 (5.7) 1.00 (ref) 2.55 (1.75, 3.72)
25–29.9 38/693 (5.5) 0.45 (0.29, 0.71) 110/2267 (4.9) 0.82 (0.62, 1.10) 1.19 (0.81, 1.75)
30–34.5 21/420 (5.0) 0.42 (0.25, 0.71) 39/887 (4.4) 0.74 (0.51, 1.10) 1.20 (0.69, 2.10)
>35 11/183 (6.0) 0.54 (0.27, 1.07) 19/280 (6.8) 1.24 (0.74, 2.06) 0.87 (0.39, 1.94)




No 115/1677 (6.9) 1.00 (ref) 242/4734 (5.1) 1.00 (ref) 1.52 (1.20, 1.93) P=0.74
Yes 13/161 (8.1) 0.99 (0.54, 1.83) 17/258 (6.6) 1.19 (0.71, 1.99) 1.27 (0.58, 2.76)
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Smoking and Smoking Cessation
After adjusting for age, current smoking among those 
with obstructive lung function was more common 
among the KYH participants in men (OR 3.30 95% CI 
1.95, 5.61) but similar in KYH/Tromsø 7 participants in 
women (OR 1.15 95% CI 0.66, 2.01). In both studies, 
the prevalence of being a current smoker was higher 
among participants reporting respiratory symptoms 
(Table 5).
Among the KYH participants who had ever smoked the 
majority of those with obstructive lung disease plus symp-
toms had been advised to stop smoking by a doctor (62/90 
68.9%). However, the proportion of these participants who 
reported they were offered assistance to stop smoking was 
much lower (7/90 8%).
Pharmacological Management
The prevalence of use of medications for COPD by study 
and reporting of respiratory symptoms is shown in Table 5. 
The majority of participants with obstructive lung function 
were not using medications for management of COPD. 
The use of medications for maintenance and for symptom 
relief was higher in those reporting respiratory symptoms 
in Tromsø 7 (test for trend p<0.001) but there was only 
weak evidence for an association between medication use 
and symptoms in KYH (test for trend p=0.12) although the 
numbers reporting any medication use were extremely low 
limiting power to detect any association. While there was 
no evidence for a difference in medication use between 
studies after adjusting for age and sex (Table 5), after 
additional adjustment for the level of reported symptoms 
Table 5 Awareness and Management by Study and Level of Self-Reported Respiratory Symptoms in Those with Obstructive Lung 
























KYH 2 (6.9) 14 (24.1) 41 (57.8) P<0.001 57 (36.1)
Tromsø 7 11 (4.6) 39 (21.2) 33 (48.5) P<0.001 83 (16.8)
Age and sex adjusted OR 
Tromsø 7/KYH (95% CI)
0.48 (0.09, 2.44) 0.70 (0.34, 1.45) 0.59 (0.29, 1.20) 0.29 (0.19, 0.44)
Currently 
smokes
KYH men 6 (33.3) 15 (53.6) 28 (75.7) P=0.003 49 (59.0)
Tromsø 7 men 19 (17.3) 30 (38.0) 24 (57.1) P<0.001 73 (31.6)
Age adjusted OR Tromsø 7/KYH 0.43 (0.13, 1.38) 0.54 (0.22, 1.36) 0.41 (0.14, 1.23) 0.30 (0.18, 0.51)
KYH women 2 (18.2) 9 (30.0) 15 (44.1) P=0.03 26 (34.7)
Tromsø 7 women 33 (24.6) 36 (30.8) 17 (50.0) P=0.008 86 (30.2)
Age adjusted OR Tromsø 7/ 
KYH
1.00 (0.19, 5.26) 1.13 (0.45, 2.85) 1.71 (0.52, 5.59) 0.87 (0.50, 1.51)
Maintenance 
treatmenta
KYH 1 (3.7) 4 (7.3) 9 (12.9) P=0.12 14 (9.2)
Tromsø 7 17 (6.9) 31 (15.8) 28 (36.8) P<0.001 76 (14.7)








KYH 0 (0.0) 2 (3.6) 5 (7.1) P=0.12 7 (4.6)
Tromsø 7 6 (2.4) 17 (8.7) 15 (19.7) P<0.001 38 (7.3)
Age and sex adjusted OR 
Tromsø 7/KYH
- 3.18 (0.68, 14.88) 4.49 (1.19, 
16.97)
1.72 (0.74, 3.98)
Notes: *Data on medication use missing in Know Your Heart for 6 participants with obstructive lung disease (1 participant with symptoms). aATC codes R03BB, A03AC12, 
13, 18, 19, R03AK, R03AL, R03DA04, R03DX07. bATC codes R03AC02, 03, 04.
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there was strong evidence that the odds of receiving main-
tenance therapy (OR 2.90 95% CI 1.48, 5.70) and short- 
acting treatments (OR 3.56 95% CI 1.43, 8.87) for symp-
toms relief were higher for participants in Tromsø 7.
Impact of Missing Data on Spirometry 
Testing
The characteristics of those who did and did not complete 
the spirometry examination in both studies are shown in 
Supplementary Table 3. The factors associated with com-
pleting spirometry differed between the two studies. In 
KYH the main factor associated with spirometry was age 
with good evidence that those with spirometry were 
younger than all participants attending the health check. 
There was also weak evidence those with spirometry were 
more highly educated, had lower BMI and reported less 
breathlessness. In Tromsø 7, there were substantial differ-
ences in age between those with and without spirometry 
but in contrast to KYH those with spirometry data were 
older in keeping with additional inclusion of those who 
attended previous examinations in the sample selection. 
There was also evidence that those with spirometry were 
more likely to be women, have lower levels of education, 
be ex-smokers, have lower BMI, and less likely to report 
existing CVD.
The prevalence of obstructive lung disease estimated in 
sensitivity analyses using multiple imputation by age and 
sex is shown in Supplementary Figures 2A and B. The 
substantive findings were not different using multiple 
imputation to complete case analysis.
Discussion
In this study comparing prevalence of obstructive lung 
function between participants aged 40–69 years taking 
part in population-based studies in Russia and Norway 
we found no evidence for a difference in obstructive 
lung function in men, but higher prevalence of obstructive 
lung function in the Norwegian compared to Russian 
women, which was explained by differences in smoking 
history. In contrast, the prevalence of COPD defined as 
both obstructive lung function and respiratory symptoms 
was higher among both men and women in the Russian 
study. There was a strikingly high prevalence of respira-
tory symptoms among Russian participants both among 
those who had an obstructive lung function pattern on 
spirometry but also in participants without obstructive 
lung function, reflecting very different patterns of symp-
tom reporting in the two populations.
The age-standardized prevalence of obstructive lung 
function (pre-bronchodilator) among the Russian partici-
pants was 11.0% using the GLI-LLN normal definition in 
men and 6.8% in women. This is higher than the findings 
from pre-bronchodilator spirometry tests reported by 
Andreeva et al in the RESPECT study in North-West 
Russia (9.6% in men 4.8% in women)13 and the Ural 
(5.8% total population).15 The findings among the 
Tromsø Study participants were also higher than estimates 
from the HUNT study from central Norway in 2006–2008 
(7.3%).19 Prevalences using a fixed cut point rather than 
LLN were more similar to a previous study from 
Novosibirsk from 2002–5 which found 19.5% (23.5% in 
men and 16.0% in women) using a broader definition of 
airway obstruction on spirometry (FEV1/FVC ratio <0.7 or 
FEV1,<80%).14 In this study, we did not find any evidence 
for a difference in the prevalence of obstructive lung 
function between men in the Russian and Norwegian stu-
dies. This is surprising given historically very high smok-
ing prevalence among Russian men.7 Despite recent 
declines in smoking in Russia,28 we did find here that 
the prevalence of current smoking and pack-year history 
was higher among the Russian than the Norwegian men. 
However, there was also a high prevalence of ex-smokers 
in the Norwegian sample therefore the current lung func-
tion damage in this sample could be attributable to higher 
levels of smoking in Norway in the past. There was no 
statistical evidence for a higher burden of airway obstruc-
tion in the Russian men, although the actual prevalence 
was slightly higher in the older ages group (60–69 years). 
The lower than anticipated estimates of obstructive lung 
function in Russian men found here and in previous stu-
dies are difficult to interpret but given the very high pre-
mature CVD mortality in Russian men in this age range, 
differential survival may play a role. There was no evi-
dence for an association with COPD and self-report of MI 
or stroke in this study in keeping with this, however it is 
important to note our measure was based on self-reported 
disease only which could have been affected by measure-
ment error, there was a small number of cases and we did 
not include a detailed investigation of the relationships 
with all CVD outcomes. The high burden of CVD mortal-
ity in Russia makes investigation of cardiovascular and 
respiratory co-morbidity in this population an important 
area to investigate in more depth. Prospective studies to 
investigate the incidence of COPD are also needed.
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In contrast to findings from spirometry testing, there 
were striking differences between the Russian and 
Norwegian participants with regards to reporting of symp-
toms. The high burden of respiratory symptoms in the 
Russian study population is important given increasing 
evidence that respiratory symptoms among smokers are 
associated with poorer outcomes including a higher rate 
of respiratory infections, impaired exercise capacity, air-
way thickening, and poorer quality of life even in the 
absence of obstructive lung function on spirometry.29,30 
In a prospective study of 596 smokers and former smokers 
aged 70–79 years mortality was similar in those with 
dyspnoea but no obstructive lung function compared to 
those with obstructive lung function without dyspnoea.31 
Several previous studies have found the prevalence of 
reported respiratory symptoms is very high in Russia con-
sistent with the levels of breathlessness and chronic cough 
found here.10–13 Only two of these studies also included 
findings from spirometry. In the study by Chuchalin et al 
spirometry was only conducted in those who reported 
either respiratory symptoms or risk factors, of whom 
21.8% also had airway obstruction.11 Andreeva et al 
reported on data from both lung function testing and 
respiratory symptoms and found that the positive predic-
tive value of respiratory symptoms for identifying obstruc-
tive lung function was low (8%)13 which was similar to 
findings in this study in both Russian (10%) and 
Norwegian participants (14%). Here we also found a 
high prevalence of respiratory symptoms in the Russian 
study population in those without obstructive lung func-
tion suggesting there are other explanations aside from 
COPD per se for high burden of respiratory symptoms 
found here and in previous studies in Russia. The symp-
toms considered here (cough and breathlessness) are non- 
specific and may be caused by many factors including both 
other respiratory diseases (for instance lower respiratory 
tract infection was the 6th and tuberculosis the 18th lead-
ing cause of death in Russia in 20161) and non-respiratory 
causes. For example, the differences in levels of breath-
lessness in the population may be related to anxiety, phy-
sical fitness, levels of obesity or other co-morbidities in 
particular heart failure. Differences in air pollution may 
also play an important role as well as possible cultural 
differences in the interpretation or perception of symp-
toms. The lower levels of use of medications found here 
among the Russian participants with obstructive lung func-
tion could also be a factor with differences in management 
influencing levels of symptom control. Due to the cross- 
sectional nature of the data, we could not investigate this 
hypothesis here due to strong possibility of confounding 
by indication (those with symptoms were more likely to 
receive medication due to increased need).
The presence of respiratory symptoms in those with 
obstructive lung function was important when comparing 
awareness and management of COPD between the two 
studies. Among those with obstructive lung disease, 
respiratory symptoms were associated in a dose-response 
manner with higher awareness of disease, smoking and 
among the Norwegian participants the use of medications 
for management of COPD. The relatively large asympto-
matic group of Norwegian participants with obstructive 
lung disease as defined by spirometry were less likely to 
report a diagnosis or any pharmacological treatment. 
However, higher levels of awareness among the Russian 
participants did not translate into correspondingly better 
pharmacological management as levels of pharmacologi-
cal treatment were low while many participants continued 
to smoke. Smoking cessation is a key part of the manage-
ment of COPD. The prevalence of smoking in those with 
obstructive lung function was particularly high in the 
Russian men (59% current smokers) compared to approxi-
mately 30% in the Norwegian participants and Russian 
women. In the KYH study, some additional questions 
about smoking cessation were asked to smokers. While 
the majority of the Russian participants who had both 
obstructive lung function and respiratory symptoms had 
been advised by a doctor to stop smoking, only 8% of this 
high-risk group reported they had been offered assistance 
to stop. Increasing the availability of smoking cessation 
treatments could have a substantial benefit in reducing the 
burden from COPD and other smoking-related disease.
This study has several limitations which should be 
considered on interpreting the findings:
First, here we have estimated prevalence of obstructive 
lung function (with respiratory symptoms) in participants 
in population-based studies. It is likely the findings may 
have been affected by selection bias. While we investi-
gated the potential impact on the findings of using a sub- 
set of participants and found no evidence that this had a 
substantial impact of the prevalence of obstructive lung 
disease, there may still be bias in the extent to which 
participants are representative of their respective popula-
tions. The proportion of invited participants who took part 
in the studies overall was 22% for Novosibirsk, 60% for 
Arkhangelsk21 and 65% for Tromsø 7.32 It is plausible 
attendance was differential by lung function status, as 
International Journal of Chronic Obstructive Pulmonary Disease 2021:16                                                https://doi.org/10.2147/COPD.S292472                                                                                                                                                                                                                       
DovePress                                                                                                                       
1365
Dovepress                                                                                                                                                            Cook et al

















































































those with very severe respiratory disease may be less 
likely to take part. Any selection bias will have affected 
the prevalence estimates reported here and these should be 
interpreted with caution. Furthermore, the studies took 
place in two cities in Russia and one municipality in 
Norway, therefore prevalence estimates may not be gen-
eralizable to the whole of both countries. However, com-
parisons of use of COPD medication as maintenance 
treatment within the Norwegian Prescription Database 
(NorPD) show that use in the Troms and Finnmark county 
was very close to Norway as a whole in 2016.33
Secondly, in both studies only pre-bronchodilator 
spirometry was conducted while for a diagnosis of 
COPD spirometry should also be conducted post-bronch-
odilator in order to demonstrate irreversible airflow limita-
tion, therefore some participants with reversible airflow 
limitation may have been misclassified. Sputum produc-
tion was also not assessed in either study. The two studies 
used different spirometry devices which may have limited 
the comparability of the results although protocols for data 
collection were similar and procedures for quality control 
were harmonised. The questions on chronic cough were 
also not identical although the questions on breathlessness 
in both studies were measured using the same standardized 
tool. Translation of the questions on breathlessness to 
Russian and Norwegian were cross-checked by a speaker 
of both languages and found to be consistent in meaning. 
While measurement error due to differences in how ques-
tions on respiratory symptoms were asked is possible it 
does not seem sufficient to account for the huge differ-
ences in reporting of symptoms observed in this study. 
However, cultural differences in the perception of symp-
toms for example understanding of the concept of breath-
lessness may play a role in accounting for the large 
population level differences observed in this study. 
Finally, we were restricted in assessing management to 
pharmacological management and have not been able to 
compare other non-pharmacological aspects of COPD 
management such as participation in pulmonary rehabilita-
tion programmes.
In conclusion, we have found that the burden of 
obstructive lung disease on spirometry was similar in 
participants taking part in population-based studies in 
Norway and Russia but there was a strikingly high burden 
of respiratory symptoms among the Russian participants. 
Further work is needed to understand the reasons and 
implications for health of this high prevalence of chronic 
cough and breathlessness. The contribution of 
cardiovascular disease, in particularly heart failure, here 
as well as further understanding of the burden of respira-
tory and cardiovascular co-morbidity are important areas 
to investigate. There were low levels of smoking cessation 
and use of medications in both study populations in parti-
cipants identified with COPD indicating management of 
COPD could be improved in both countries.
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